Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.6600
+0.05048.27%
Post-market: 0.66000.00000.00%19:13 EDT
Volume:306.50K
Turnover:191.12K
Market Cap:7.31M
PE:1.25
High:0.6700
Open:0.5913
Low:0.5900
Close:0.6096
Loading ...

PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025

PR Newswire
·
11 Mar

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PR Newswire
·
10 Mar

BRIEF-Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Reuters
·
06 Mar

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

THOMSON REUTERS
·
06 Mar

Lucid Diagnostics Prices $15.3 Million Direct Offering

MT Newswires Live
·
04 Mar

Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering

TIPRANKS
·
04 Mar

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

PR Newswire
·
04 Mar

BRIEF-Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21 - SEC Filing

Reuters
·
01 Mar

Renowned Investigators Awarded $8 Million Nih Grant to Study Lucid Diagnostics' Esoguard® in at-Risk Patients Without Symptomatic Gerd

THOMSON REUTERS
·
27 Feb

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PR Newswire
·
27 Feb

Lucid Diagnostics Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
25 Feb

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire
·
25 Feb

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

THOMSON REUTERS
·
24 Feb

Press Release: PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Dow Jones
·
24 Feb

BRIEF-PAVmed Regains Compliance With Nasdaq Stockholders' Equity Requirement

Reuters
·
18 Feb

PAVmed Regains Compliance With Nasdaq Listing Standards

MT Newswires Live
·
18 Feb